نتائج البحث

1

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

المؤلفون: Stefania Paolini, Francesco Barbato, Sarah Parisi, Chiara Sartor, Valentina Robustelli, Giovanni Marconi, Nicoletta Testoni, Antonio Curti, Mario Arpinati, Gianluca Cristiano, Michele Cavo, Simona Soverini, Jacopo Nanni, Elisabetta Zappone, Gabriella Chirumbolo, Cristina Papayannidis, Francesca Bonifazi, Carolina Terragna, Alida Dominietto

المساهمون: Papayannidis C., Sartor C., Dominietto A., Zappone E., Arpinati M., Marconi G., Cristiano G., Nanni J., Parisi S., Barbato F., Paolini S., Soverini S., Terragna C., Robustelli V., Testoni N., Chirumbolo G., Curti A., Cavo M., Bonifazi F.

المصدر: Hematological Oncology. 39:580-583

مصطلحات موضوعية: Adult, Male, Cancer Research, Adolescent, Prognosi, Lymphoblastic Leukemia, donor lymphocyte infusion, acute lymphoblastic leukemia, Donor lymphocyte infusion, Follow-Up Studie, Young Adult, Antineoplastic Agents, Immunological, Retrospective Studie, stem cell transplant, medicine, Humans, Inotuzumab Ozogamicin, Retrospective Studies, Salvage Therapy, Inotuzumab ozogamicin, business.industry, Hematology, General Medicine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prognosis, Combined Modality Therapy, Survival Rate, Oncology, Lymphocyte Transfusion, Cancer research, Female, Neoplasm Recurrence, Local, Stem cell, business, Follow-Up Studies, Human, Stem Cell Transplantation, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcec9b82ad040c7e50d330235ff1549Test
https://doi.org/10.1002/hon.2886Test

2

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia

المؤلفون: Sarah Parisi, Chiara Sartor, Gianluca Cristiano, Antonio Curti, Annalisa Talami, Emanuela Ottaviani, Jayakumar Vadakekolathu, Matteo Olivi, Sarah Wagner, Simone Ragaini, Michele Cavo, Cristina Papayannidis, Giovanni Marconi, Stefania Paolini, Jacopo Nanni, Sergio Rutella, Darina Očadlíková, Giulia Corradi, Marilena Ciciarello

المصدر: Blood Advances

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b122fd8347e3a6c8645b078ac603ba7fTest
http://europepmc.org/articles/PMC8753212Test

3

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

المساهمون: Harvard Medical School [Boston] (HMS), Hospital Universitari Germans Trias I Pujol [Badalona], Università degli studi di Torino = University of Turin (UNITO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Bologna/Università di Bologna, Clínica Universidad de Navarra [Pamplona], Centre hospitalier universitaire de Poitiers (CHU Poitiers), University of Florida [Gainesville] (UF), Memorial Sloane Kettering Cancer Center [New York], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université d'Angers (UA), Université de Nantes (UN), Site de Recherche Intégrée sur le Cancer [Nantes] (SIRIC), Centre hospitalier universitaire de Nantes (CHU Nantes), SIRIC ILIAD [Angers, Nantes], Hospital Universitario Quironsalud, Rush University Medical Center [Chicago], Baylor Scott & White Charles A. Sammons Cancer Center [Dallas, TX, USA], Oncology Institute of Hope and Innovation [Glendale, CA, USA] (OIHI), University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Novant Health Forsyth Medical Center [Winston-Salem, NC, USA] (NHFMC), Oncopeptides AB [Stockholm, Sweden], Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain] (IBSAL/CIC), HORIZON (OP-106) Investigators, Bernardo, Elizabeth, Università degli studi di Torino (UNITO), University of Bologna, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Richardson P.G., Oriol A., Larocca A., Blade J., Cavo M., Rodriguez-Otero P., Leleu X., Nadeem O., Hiemenz J.W., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Moreb J.S., Anderson K.C., Laubach J.P., Thuresson S., Thuresson M., Byrne C., Harmenberg J., Bakker N.A., Mateos M.-V.

المصدر: Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2021, 39 (7), pp.757-767. ⟨10.1200/JCO.20⟩
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

مصطلحات موضوعية: Adult, Male, Cancer Research, Time Factors, Time Factor, Phenylalanine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tumor cells, Drug resistance, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Recurrence, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm, Progression-free survival, Melphalan, Aged, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, Antineoplastic Combined Chemotherapy Protocol, business.industry, Refractory Multiple Myeloma, Middle Aged, medicine.disease, Progression-Free Survival, United States, 3. Good health, Europe, Clinical trial, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Disease Progression, Cancer research, Female, Multiple Myeloma, business, Human, Conjugate, medicine.drug

وصف الملف: application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79bb7c110aefa09f245d7dfe112c3ba4Test
https://doi.org/10.1200/jco.20.02259Test

4

Treatment of multiple myeloma-related bone disease

المؤلفون: Michele Cavo, Ioannis Ntanasis-Stathopoulos, Charalampia Kyriakou, Brian G.M. Durie, Jesús F. San-Miguel, Fredrik Schjesvold, Philippe Moreau, Sonja Zweegman, Noopur Raje, Evangelos Terpos, Nikhil C. Munshi, Matthew T. Drake, Meletios A. Dimopoulos, Elena Zamagni, Suzanne Lentzsch, Niels Abildgaard, Jens Hillengass, Javier de la Rubia, Ramón García-Sanz

المساهمون: Terpos E., Zamagni E., Lentzsch S., Drake M.T., Garcia-Sanz R., Abildgaard N., Ntanasis-Stathopoulos I., Schjesvold F., de la Rubia J., Kyriakou C., Hillengass J., Zweegman S., Cavo M., Moreau P., San-Miguel J., Dimopoulos M.A., Munshi N., Durie B.G.M., Raje N.

المصدر: Terpos, E, Zamagni, E, Lentzsch, S, Drake, M T, García-Sanz, R, Abildgaard, N, Ntanasis-Stathopoulos, I, Schjesvold, F, de la Rubia, J, Kyriakou, C, Hillengass, J, Zweegman, S, Cavo, M, Moreau, P, San-Miguel, J, Dimopoulos, M A, Munshi, N, Durie, B G M, Raje, N & Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045Test(20)30559-3
Bone Working Group of the International Myeloma Working Group 2021, ' Treatment of multiple myeloma-related bone disease : recommendations from the Bone Working Group of the International Myeloma Working Group ', The Lancet Oncology, vol. 22, no. 3, pp. e119-e130 . https://doi.org/10.1016/S1470-2045Test(20)30559-3

وصف الملف: ELETTRONICO

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087f0958cccbc7e19db18e9c77a57d23Test
http://www.scopus.com/inward/record.url?scp=85101284824&partnerID=8YFLogxKTest

5

Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement

المؤلفون: Jacopo Nanni, Cristina Papayannidis, Antonio Curti, Francesco Barbato, Stefania Paolini, Sarah Parisi, Michele Cavo, Francesca Bonifazi, Mario Arpinati, Gianluca Cristiano, Giovanni Marconi, Chiara Sartor

المساهمون: Cristiano G., Nanni J., Sartor C., Parisi S., Marconi G., Barbato F., Arpinati M., Bonifazi F., Curti A., Cavo M., Paolini S., Papayannidis C.

المصدر: Acta Haematologica. 144:688-692

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Fusion Proteins, bcr-abl, Protein Kinase Inhibitor, Chromosomal translocation, Hematopoietic stem cell transplantation, Philadelphia chromosome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, chemistry.chemical_compound, Bone Marrow, Positron Emission Tomography Computed Tomography, hemic and lymphatic diseases, Internal medicine, Medicine, Imidazole, Chemotherapy, Acute leukemia, business.industry, Ponatinib, Myeloid leukemia, Hematology, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, chemistry, Nelarabine, Pyridazine, business, T-cell acute lymphoblastic leukemia, Human, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9817e9a4d94ebcf35ffc08bcc79cc94eTest
https://doi.org/10.1159/000516003Test

6

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

المؤلفون: Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino

المساهمون: Tacchetti P., Pantani L., Patriarca F., Petrucci M.T., Zamagni E., Dozza L., Galli M., Di Raimondo F., Crippa C., Boccadoro M., Barbato S., Tosi P., Narni F., Montefusco V., Testoni N., Spadano A., Terragna C., Pescosta N., Marzocchi G., Cellini C., Galieni P., Ronconi S., Gobbi M., Catalano L., Lazzaro A., De Sabbata G., Cangialosi C., Ciambelli F., Musto P., Elice F., Cavo M., Fanin R., Foa' R., Rambaldi A., Rossi G., Leoni P., Corradini P., Torelli G., Fioritoni G., Cortelazzo S., Lambertenghi Deliliers G., La Nasa G., Zaccaria A., De Fabritiis P., Cascavilla N., Bosi A., Semenzato G., Gugliotta L., Gherlinzoni F., Angelucci E., Martelli M.F., Petti M.C., Leone G., Carella A.M., Ciceri F., Santoro A., Ferrara F., Nobile F., D'Arco A.M., Levis A., Guardigni L., Gallamini A., Fattori P.P., Morandi S., Amadori D., Rotoli B., Mirto S., Paladini G., Mozzana R., Pinotti G., Rodeghiero F., Cantore N., Pavone V., Pogliani E.M., Liberati A.M., Majolino I., Amadori S., Lauria F., Aglietta M., Quarta G., Storti S., Morabito F., Capalbo S.F., Gianni A.M., Mettivier V., Rizzoli V., Bernasconi C., Visani G., Pizzuti M., La Verde G., Avvisati G., Longinotti M., Gallo E., Dammacco F., Russo D., Bacigalupo A., Musolino C.

المصدر: The Lancet Haematology. 7:e861-e873

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Phases of clinical research, Transplantation, Autologous, Dexamethasone, Bortezomib, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, GIMEMA-MMY-3006 trial, bortezomib, thalidomide, dexamethasone, VTD, double autologous haematopoietic stem-cell transplantation, multiple myeloma, Multiple myeloma, Aged, Intention-to-treat analysis, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Thalidomide, Transplantation, Regimen, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, Follow-Up Studies, 030215 immunology, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d247cf6931cb796a2568e2552250ca02Test
https://doi.org/10.1016/s2352-3026Test(20)30323-9

7

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

المؤلفون: Michele Cavo, Vania Hungria, Bart Heeg, Andrea Garcia, Meletios A. Dimopoulos, Mariana Fernandez, Deborah M. Martínez-Baños, Maria-Victoria Mateos, Jianming He, Gerardo Machnicki, Annette Lam

المساهمون: Hungria V., Martinez-Banos D.M., Mateos M.-V., Dimopoulos M.A., Cavo M., Heeg B., Garcia A., Lam A., Machnicki G., He J., Fernandez M.

المصدر: Advances in Therapy

مصطلحات موضوعية: Male, Melphalan, 030213 general clinical medicine, medicine.medical_specialty, Population, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Multiple myeloma, Daratumumab, Propensity score matching, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Pharmacology (medical), Propensity Score, education, Aged, Retrospective Studies, Original Research, education.field_of_study, business.industry, Antibodies, Monoclonal, Standard of Care, General Medicine, Middle Aged, medicine.disease, Progression-Free Survival, Confidence interval, Hemato-Oncology Latin America, Latin America, ALYCONE, 030220 oncology & carcinogenesis, Cohort, Prednisone, Indirect treatment comparison, Female, business, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d30dae92d709ef6526889f33c6e8d32bTest
https://doi.org/10.1007/s12325-020-01521-9Test

8

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

المساهمون: Martinelli, Giovanni, Papayannidis, Cristina, Piciocchi, Alfonso, Robustelli, Valentina, Soverini, Simona, Terragna, Carolina, Marconi, Giovanni, Lemoli, Roberto Massimo, Guolo, Fabio, Fornaro, Antonella, Lunghi, Monia, de Fabritiis, Paolo, Candoni, Anna, Selleri, Carmine, Simonetti, Federico, Bocchia, Monica, Vitale, Antonella, Frison, Luca, Tedeschi, Alessandra, Cuneo, Antonio, Bonifacio, Massimiliano, Martelli, Maria Paola, D'Ardia, Stefano, Trappolini, Silvia, Tosi, Patrizia, Galieni, Piero, Fabbiano, Francesco, Abbenante, Maria Chiara, Granier, Muriel, Zhu, Zhaoyin, Wang, Mingyue, Sartor, Chiara, Paolini, Stefania, Cavo, Michele, Foà, Robin, Fazi, Paola, Vignetti, Marco, Baccarani, Michele

مصطلحات موضوعية: medicine.medical_specialty, Population, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Tyrosine kinase inhibitors, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), GIMEMA LAL 1811, medicine, Clinical endpoint, Humans, Philadelphia Chromosome, Prospective Studies, education, Adverse effect, Aged, education.field_of_study, biology, business.industry, Ponatinib, Imidazoles, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Settore MED/15, Rash, Pyridazines, Transplantation, chemistry, Alanine transaminase, biology.protein, medicine.symptom, business, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532a7ef6c6f327838c21185db5ce9234Test
http://hdl.handle.net/11567/1078678Test

9

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

المساهمون: Gay F., Musto P., Rota-Scalabrini D., Bertamini L., Belotti A., Galli M., Offidani M., Zamagni E., Ledda A., Grasso M., Ballanti S., Spadano A., Cea M., Patriarca F., D'Agostino M., Capra A., Giuliani N., de Fabritiis P., Aquino S., Palmas A., Gamberi B., Zambello R., Petrucci M.T., Corradini P., Cavo M., Boccadoro M.

مصطلحات موضوعية: Male, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Combined Modality Therapy, Cyclophosphamide, Dexamethasone, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Melphalan, Middle Aged, Multiple Myeloma, Oligopeptides, Prognosis, Survival Rate, Thalidomide, Transplantation, Autologous, chemistry.chemical_compound, Maintenance therapy, Monoclonal, Medicine, multiple myeloma, newly diagnosed, carfilzomib, cyclophosphamide, lenalidomide, dexamethasone, induction treatment, autologous stem-cell transplantation, maintenance treatment, phase 2, trial, Multiple myeloma, carfilzomib, trial, induction treatment, Oncology, Oligopeptide, newly diagnosed, Autologous, Human, medicine.drug, medicine.medical_specialty, Prognosi, autologous stem-cell transplantation, Antibodies, Follow-Up Studie, Internal medicine, Autologous transplantation, Transplantation, Antineoplastic Combined Chemotherapy Protocol, maintenance treatment, business.industry, medicine.disease, Settore MED/15, Carfilzomib, chemistry, phase 2, business

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ee9f82acbff156d6f0b7336cbb430aTest
https://hdl.handle.net/2108/318985Test

10

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde

المساهمون: Musto P., Engelhardt M., Caers J., Bolli N., Kaiser M., van de Donk N., Terpos E., Broijl A., de Larrea C.F., Gay F., Goldschmidt H., Hajek R., Vangsted A.J., Zamagni E., Zweegman S., Cavo M., Dimopoulos M., Einsele H., Ludwig H., Barosi G., Boccadoro M., Mateos M.-V., Sonneveld P., Miguel J.S.

المصدر: Musto, P, Engelhardt, M, Caers, J, Bolli, N, Kaiser, M, van de Donk, N, Terpos, E, Broijl, A, de Larrea, C F, Gay, F, Goldschmidt, H, Hajek, R, Vangsted, A J, Zamagni, E, Zweegman, S, Cavo, M, Dimopoulos, M, Einsele, H, Ludwig, H, Barosi, G, Boccadoro, M, Mateos, M V, Sonneveld, P & Miguel, J S 2021, ' 2021 European myeloma network review and consensus statement on smoldering multiple myeloma : How to distinguish (and manage) Dr. Jekyll and Mr. Hyde ', Haematologica, vol. 106, no. 11, pp. 2799-2812 . https://doi.org/10.3324/haematol.2021.278519Test
Haematologica

مصطلحات موضوعية: Smoldering Multiple Myeloma, Oncology, medicine.medical_specialty, MEDLINE, Investigació mèdica, Review Article, Disease, Blood plasma, Monoclonal Gammopathy of Undetermined Significance, Asymptomatic, law.invention, Randomized controlled trial, Risk Factors, law, Multiple myeloma, Internal medicine, medicine, Humans, Prospective Studies, Lenalidomide, business.industry, Mieloma múltiple, Drugs, Hematology, Plasma sanguini, medicine.disease, Clinical trial, Monoclonal gammopathy, International Myeloma Working Group, smoldering multiple myeloma, monoclonal gammopathy, Disease Progression, medicine.symptom, Multiple Myeloma, business, Anticossos monoclonals, Medicaments, medicine.drug

وصف الملف: application/pdf; STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c47b022b82f47471364acc9988cc3dTest
http://hdl.handle.net/2445/193238Test

تنقيح النتائج